DK532284D0 - Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser - Google Patents

Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser

Info

Publication number
DK532284D0
DK532284D0 DK532284A DK532284A DK532284D0 DK 532284 D0 DK532284 D0 DK 532284D0 DK 532284 A DK532284 A DK 532284A DK 532284 A DK532284 A DK 532284A DK 532284 D0 DK532284 D0 DK 532284D0
Authority
DK
Denmark
Prior art keywords
amino acid
peptides
determining
acid sequences
procedure
Prior art date
Application number
DK532284A
Other languages
English (en)
Other versions
DK532284A (da
DK164529C (da
DK164529B (da
Inventor
Hendrik Mario Geysen
Original Assignee
Commw Serum Lab Commission
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3770023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK532284(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commw Serum Lab Commission filed Critical Commw Serum Lab Commission
Publication of DK532284A publication Critical patent/DK532284A/da
Publication of DK532284D0 publication Critical patent/DK532284D0/da
Publication of DK164529B publication Critical patent/DK164529B/da
Application granted granted Critical
Publication of DK164529C publication Critical patent/DK164529C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
DK532284A 1983-03-08 1984-11-08 Fremgangsmaade til paavisning eller bestemmelse af et peptid indeholdende en sekvens af aminosyrer, som er antigenaktiv DK164529C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPF834883 1983-03-08
AUPF834883 1983-03-08
AU8400039 1984-03-08
PCT/AU1984/000039 WO1984003564A1 (en) 1983-03-08 1984-03-08 Method of determining antigenically active amino acid sequences

Publications (4)

Publication Number Publication Date
DK532284A DK532284A (da) 1984-11-08
DK532284D0 true DK532284D0 (da) 1984-11-08
DK164529B DK164529B (da) 1992-07-06
DK164529C DK164529C (da) 1992-11-23

Family

ID=3770023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK532284A DK164529C (da) 1983-03-08 1984-11-08 Fremgangsmaade til paavisning eller bestemmelse af et peptid indeholdende en sekvens af aminosyrer, som er antigenaktiv

Country Status (10)

Country Link
US (1) US5595915A (da)
EP (1) EP0138855B2 (da)
JP (1) JPH063445B2 (da)
AT (1) ATE69890T1 (da)
CA (1) CA1220420A (da)
DE (1) DE3485299D1 (da)
DK (1) DK164529C (da)
NO (1) NO166466C (da)
NZ (1) NZ207394A (da)
WO (1) WO1984003564A1 (da)

Families Citing this family (488)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) * 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US5998578A (en) * 1984-05-18 1999-12-07 New England Medical Center Hospitals, Inc. Biologically active fragments of IL-1β
AU592311B2 (en) * 1984-07-24 1990-01-11 Coselco Mimotopes Pty Ltd Method for determining mimotopes
DE3586772T2 (de) * 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
AU592560B2 (en) * 1985-04-22 1990-01-18 Coselco Mimotopes Pty Ltd Improved method for determining mimotopes
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
EP0241487B1 (en) * 1985-08-28 1998-04-22 PIECZENIK, George Method and means for sorting and identifying biological information
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
IE64356B1 (en) * 1986-07-28 1995-07-26 Bioscience Int Inc Diagnosis severity prediction and monitoring of disease by immunoassay of free activation peptides of pancreatic zymogens
GB8709274D0 (en) * 1987-04-16 1987-05-20 Wellcome Found Peptides
US4981782A (en) * 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US7811751B2 (en) 1988-05-03 2010-10-12 Oxford Gene Technology Limited Analysing polynucleotide sequences
US6054270A (en) * 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
FR2631451A1 (fr) * 1988-05-13 1989-11-17 Inst Nat Sante Rech Med Procede de caracterisation de l'epitope intervenant dans une reaction antigene anticorps, kit ou necessaire pour la mise en oeuvre du procede
US5003043A (en) * 1988-05-25 1991-03-26 Triton Biosciences Inc. Peptides representing epitopic sites for the major HTLV-I envelope protein, antibodies thereto, and uses thereof
DE3911794A1 (de) * 1989-04-11 1990-10-18 Thomae Gmbh Dr K Monoklonale antikoerper gegen rekombinaten humanen gewebeplasminogenaktivator mit definierter epitopspezifitaet, deren herstellung und deren verwendung
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5243030A (en) * 1989-05-24 1993-09-07 Sri International Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection
US5286789A (en) * 1989-05-26 1994-02-15 Applied Immune Sciences, Inc. Solid phase multiple peptide synthesis
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
AU640400B2 (en) * 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
DE3935572A1 (de) * 1989-10-25 1991-05-02 Biotechnolog Forschung Gmbh Verfahren zur peptidsynthese und traeger dafuer
FI910245A (fi) * 1990-01-24 1991-07-25 United Biomedical Inc Syntetiska peptidkompositioner med immunoreaktivitet mot htlv-antikroppar.
US5366862A (en) * 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2090860C (en) * 1990-11-21 2003-09-16 Richard A. Houghten Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
ATE244065T1 (de) * 1990-12-06 2003-07-15 Affymetrix Inc Verfahren und reagenzien für immobilisierten polymersynthese in sehr grossem masstab
AU664385B2 (en) * 1991-08-21 1995-11-16 Receptor Laboratories, Inc. Method for generating and screening useful peptides
JPH07501929A (ja) * 1991-08-23 1995-03-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴマーフラグメントの合成非ランダム化
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
US5770358A (en) * 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
US5811246A (en) * 1991-12-17 1998-09-22 The Research Foundation Of State University Of New York Process for immobilization onto the surfaces of ELISA plates of a compound carrier complex and for immunization
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
EP0582450A3 (en) * 1992-08-03 1994-11-23 Rohto Pharma Antibodies against oxytocin receptor and their production.
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5559023A (en) * 1994-02-10 1996-09-24 Cancer Institute Tumor suppressor gene
US5834245A (en) * 1994-07-29 1998-11-10 Cancer Institute PRLTS proteins and DNA's encoding the same
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
AU691958B2 (en) 1994-08-12 1998-05-28 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
US6489460B1 (en) 1996-03-07 2002-12-03 Eisai Company, Ltd. Cloned DNA encoding mammalian occludins
JP3894381B2 (ja) * 1996-04-10 2007-03-22 株式会社ペプチド研究所 抗Ｇｌｕ▲１７▼−オステオカルシン抗体
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
GB2321642B8 (en) 1996-10-01 2006-08-22 Geron Corp Human telomerase reverse transcriptase promoter
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20050202499A1 (en) 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
EP1114864B9 (en) 1996-12-13 2013-05-08 Schering Corporation Mammalian cell surface antigens, related reagents
JP3618497B2 (ja) * 1996-12-27 2005-02-09 富士通株式会社 タンパク質の抗原決定基予測方法及びシステム
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
AR014891A1 (es) 1997-07-09 2001-04-11 Schering Corp Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
EP1798287A3 (en) 1997-08-01 2007-11-14 Schering Corporation Mammalian cell membrane proteins and related reagents
CA2382506A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Novel polypeptides and nucleic acids encoding pro293 which are useful for treating disorders of the pancreas
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
IL136216A0 (en) 1997-12-03 2001-05-20 Genentech Inc Polypeptides and nucleic acids encoding the same
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
WO1999046598A1 (en) 1998-03-10 1999-09-16 The Regents Of The University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6322976B1 (en) 1998-05-28 2001-11-27 Medical Research Council Compositions and methods of disease diagnosis and therapy
EP2360271A1 (en) * 1998-06-24 2011-08-24 Illumina, Inc. Decoding of array sensors with microspheres
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1115867A1 (en) 1998-09-21 2001-07-18 Schering Corporation Human interleukin-b50. therapeutic uses
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US7510841B2 (en) * 1998-12-28 2009-03-31 Illumina, Inc. Methods of making and using composite arrays for the detection of a plurality of target analytes
ATE420894T1 (de) 1999-03-11 2009-01-15 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
KR100504305B1 (ko) 1999-03-23 2005-07-28 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
EP1684077A1 (en) * 1999-05-14 2006-07-26 McGill University Method for identifying modulators of interacting proteins
JP2002544522A (ja) * 1999-05-14 2002-12-24 マクギル ユニバーシティー タンパク質間相互作用並びに相互作用するタンパク質および相互作用部位のアミノ酸配列を同定する方法
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
MXPA02001146A (es) 1999-07-30 2002-08-20 Schering Corp Citosinas de mamifero, reactivos relacionados.
CA2382045A1 (en) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
EP1905832A3 (en) 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
IL148936A0 (en) 1999-10-20 2002-09-12 Genentech Inc Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
DE19953775A1 (de) 1999-11-09 2001-05-10 Bayer Ag Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
DE60137829D1 (de) 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
US7582420B2 (en) * 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
EP1125905A1 (en) * 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ES2372809T3 (es) 2000-04-12 2012-01-26 Vib Vzw Uso de vegf 165 y homólogos para tratar trastornos de neurona.
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
EP1297016B1 (en) 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US6573370B1 (en) 2000-05-19 2003-06-03 Regents Of The University Of Michigan PON3 and uses thereof
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
AU2001275411B2 (en) 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
ATE432350T1 (de) 2000-06-16 2009-06-15 Incyte Corp G-protein gekoppelte rezeptoren
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002024325A2 (en) 2000-09-25 2002-03-28 Picoliter, Inc. Acoustic ejection of fluids from a plurality of reservoirs
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
EP1197755A1 (en) * 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
CA2818654A1 (en) * 2000-10-20 2002-04-25 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
WO2002072601A2 (en) * 2001-02-07 2002-09-19 The Burnham Institute Apoptosis modulator bcl-b and methods for making and using same
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20020160527A1 (en) 2001-02-26 2002-10-31 3M Innovative Properties Company Combinatorial library comprising pouches as packages for library members and method therefor
US6849449B2 (en) 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
US7514263B2 (en) 2001-04-02 2009-04-07 3M Innovative Properties Company Continuous process for the production of combinatorial libraries of materials
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
DE60230868D1 (de) * 2001-04-26 2009-03-05 Biogen Inc Criptoblockierende antikörper und deren verwendung
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100788092B1 (ko) 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
JP2005501536A (ja) 2001-07-18 2005-01-20 バイオノミックス リミテッド イオンチャネルにおける変異
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
NZ531570A (en) 2001-09-27 2006-03-31 Bionomics Ltd DNA sequences for human angiogenesis genes
US7354898B2 (en) 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
ES2401425T3 (es) 2001-10-25 2013-04-19 Medical Research Council Moléculas
DK1439863T3 (da) 2001-10-29 2011-03-14 Boehringer Ingelheim Int MNK-kinase-homologe proteiner, som er involveret i reguleringen af energihomeostase og organelmetabolisme
US7462472B2 (en) 2001-11-02 2008-12-09 The University Of Chicago Methods and compositions relating to anthrax pathogenesis
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
WO2003057728A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
AU2003222225A1 (en) 2002-02-20 2003-09-09 Incyte Corporation Receptors and membrane-associated proteins
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8008463B2 (en) 2002-04-19 2011-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnostics and therapeutics for hydrocephalus
US7445894B2 (en) * 2002-05-03 2008-11-04 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
US20040171034A1 (en) * 2002-05-03 2004-09-02 Brian Agnew Compositions and methods for detection and isolation of phosphorylated molecules
CN1665790A (zh) * 2002-05-03 2005-09-07 莫莱丘莱尔探针公司 用于检测和分离磷酸化分子的组合物及方法
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2003103725A1 (en) 2002-06-07 2003-12-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004024068A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1562587A4 (en) 2002-09-11 2006-07-19 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
CA2499123A1 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
JP4118877B2 (ja) 2002-10-22 2008-07-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE545428T1 (de) 2002-12-16 2012-03-15 Develogen Ag Pik4cb involviert in der regulierung des energiestoffwechsels
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
WO2004065000A1 (en) * 2003-01-21 2004-08-05 Illumina Inc. Chemical reaction monitor
US6910785B2 (en) * 2003-01-22 2005-06-28 Cooper Technologies Company Industrial luminaire with prismatic refractor
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US20040185499A1 (en) * 2003-03-20 2004-09-23 Jolley Michael E. Method of epitope scanning using fluorescence polarization
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2003901511A0 (en) 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
CN1802432A (zh) 2003-04-23 2006-07-12 赫希玛有限公司 昆虫胰凝乳蛋白酶及其抑制剂
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
US7173010B2 (en) 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
BR0318307A (pt) 2003-05-21 2006-07-11 Ares Trading Sa polipeptìdeo, molécula de ácido nucleico purificado, vetor, célula hospedeira, ligante, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, métodos para tratar uma doença para monitorar o tratamento terapêutico de doença em um paciente, método para a identificação de um composto que é efetivo no tratamento e/ou diagnóstico de doença, kit, e, animal não-humano transgênico ou knockout
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
US20060241035A1 (en) 2003-07-11 2006-10-26 Daria Onichtchouk Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome
WO2005014022A1 (en) 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
AU2004203373A1 (en) 2003-07-25 2005-02-10 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1678194T3 (da) 2003-10-10 2013-10-07 Alchemia Oncology Pty Ltd Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
WO2005047478A2 (en) 2003-11-12 2005-05-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
EP2412725A3 (en) 2003-11-17 2012-04-25 Genentech, Inc. Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
US20070107073A1 (en) 2003-11-19 2007-05-10 Develogen Aktiengesellschaft Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
DK2096120T3 (da) 2004-02-20 2012-07-09 Develogen Ag Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
EP2314621B1 (en) 2004-05-27 2014-03-05 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
WO2006009241A1 (ja) 2004-07-22 2006-01-26 Eisai Co., Ltd. Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー
US7869958B2 (en) 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
EP2298897B1 (en) 2004-09-02 2013-08-14 Yale University Regulation of oncogenes by microRNAs
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
WO2006060871A1 (en) 2004-12-10 2006-06-15 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
EP1838350B1 (en) 2005-01-20 2014-08-20 Ryboquin Company Limited Modulators of itch ubiquitinase activity
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
JP2008535796A (ja) 2005-03-10 2008-09-04 ジェネンテック・インコーポレーテッド 脈管の完全性を調節するための方法及び組成物
EP1863531A1 (en) 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
SI1869085T1 (sl) 2005-03-24 2012-07-31 Thrombogenics Nv Nova anti PLGF protitelesa
US20060246576A1 (en) * 2005-04-06 2006-11-02 Affymetrix, Inc. Fluidic system and method for processing biological microarrays in personal instrumentation
CA2602022C (en) 2005-04-19 2016-03-22 Gabriel Stavros Panayi Binding immunoglobulin protein (bip) for prevention or treatment of bone conditions or diseases
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
TW200643171A (en) 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
DK2407484T3 (da) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Terapeutisk pro-apoptotisk BH3-lignende molekyler og fremgangsmåder til at generere og/eller udvælge disse
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
US20100203505A1 (en) 2005-08-18 2010-08-12 Eisai R&D Management Co., Ltd. DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2
BRPI0616438A2 (pt) 2005-09-29 2012-12-25 Eisai R&D Man Co Ltd proteÍna, polinucleotÍdeo, anticorpo contra uma proteÍna secretora ou de membrana, ou um fragmento funcional do mesmo, hibridoma, agente terapÊutico para uma doenÇa autoimune, agente para inibir adesço de cÉlulas t, e, mÉtodo para triar uma substÂncia
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR101453570B1 (ko) 2005-12-02 2014-10-22 제넨테크, 인크. Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US20090012029A1 (en) 2006-01-06 2009-01-08 Hussey Richard S Cyst Nematode Resistant Transgenic Plants
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP3360965A1 (en) 2006-01-20 2018-08-15 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
WO2007106991A1 (en) 2006-03-17 2007-09-27 Mcgill University Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP5033121B2 (ja) 2006-04-11 2012-09-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドーパミン産生ニューロン前駆細胞マーカー１８７ａ５
EP2447360A1 (en) 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007121522A1 (en) 2006-04-21 2007-11-01 Minister for Primary Industries For And On Behalf Of The State Of New South Wales Pestivirus species
US7723564B2 (en) 2006-05-10 2010-05-25 Board Of Regents Of The University Of Nebraska Compositions and methods for modulation of KSR1 and KSR2 interactions
US20080003667A1 (en) * 2006-05-19 2008-01-03 Affymetrix, Inc. Consumable elements for use with fluid processing and detection systems
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
KR20200058579A (ko) 2006-06-06 2020-05-27 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
EP2069791B1 (en) 2006-07-27 2012-01-25 University of Maryland, Baltimore Cellular receptor for antiproliferative factor
EP2434017A3 (en) 2006-08-01 2012-09-05 Board of Regents of the University of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
SG174773A1 (en) 2006-09-07 2011-10-28 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
US20080249083A1 (en) 2006-09-21 2008-10-09 Probiodrug Ag Novel genes related to glutaminyl cyclase
WO2008035527A1 (fr) * 2006-09-21 2008-03-27 Mmt Co., Ltd. ANTICORPS MONOCLONAL ANTI-C1q
US20100166743A1 (en) 2006-10-06 2010-07-01 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
MX2009004664A (es) 2006-11-02 2009-10-12 Daniel J Capon Inmunoglobulinas hibridas con partes moviles.
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
PL2120997T3 (pl) 2006-12-21 2017-08-31 H. Lundbeck A/S Modulacja aktywności proneurotrofin
WO2008094370A2 (en) 2006-12-22 2008-08-07 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
JPWO2008111464A1 (ja) 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
WO2008111466A1 (ja) 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
CA2691166A1 (en) 2007-06-27 2008-12-31 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
MX2010001217A (es) 2007-07-31 2010-04-07 Regents The Unuversity Of Texa Familia de micro-arn que modula la fibrosis y usos de la misma.
CA2700162C (en) 2007-09-25 2018-08-14 Pastoral Greenhouse Gas Research Ltd Cell-permeabilising peptides and polypeptides for microbial cells
JP5566293B2 (ja) 2007-10-04 2014-08-06 バイオノミックス リミテッド 内皮細胞マーカーおよびその使用
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
PT2514436T (pt) 2007-11-07 2018-03-21 Genentech Inc Il-22 para utilização no tratamento de distúrbios microbianos
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
US20110177502A1 (en) 2008-02-19 2011-07-21 Hakon Hakonarson Identification of pediatric onset inflammatory disease loci and methods of use thereof for the diagnosis and treatment of the same
GB0804702D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
CN102036689B (zh) 2008-03-17 2014-08-06 得克萨斯系统大学董事会 神经肌肉突触维持和再生中涉及的微小rna的鉴定
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
JP2011529708A (ja) 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CN102239178B (zh) 2008-10-02 2017-06-23 Vib研究所 抑制PlGF以治疗费城染色体阳性白血病
CN102245773B (zh) * 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
CN102272157B (zh) 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
RU2746478C2 (ru) 2008-12-04 2021-04-14 КьюРНА, Инк. Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CN102317458B (zh) 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2391748A4 (en) * 2009-01-28 2012-08-01 Antigen Express Inc LI-KEY HYBRID PEPTIDES MODULATING IMMUNE RESPONSE TO FLU
PT2396038E (pt) 2009-02-12 2016-02-19 Curna Inc Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
CA2744236C (en) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
ES2656290T3 (es) 2009-03-16 2018-02-26 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
RU2011142182A (ru) 2009-03-19 2013-04-27 Медикал Рисерч Каунсил Текнолоджи Соединения
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101722541B1 (ko) 2009-05-06 2017-04-04 큐알엔에이, 인크. Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
US9012139B2 (en) 2009-05-08 2015-04-21 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
JP5813629B2 (ja) 2009-05-11 2015-11-17 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
CA2762369C (en) 2009-05-18 2021-12-28 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
EP2432882B1 (en) 2009-05-22 2019-12-25 CuRNA, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2443237B1 (en) 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (ja) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
EP2443459B1 (en) 2009-06-19 2018-12-26 The Arizona Board of Regents, A Body Corporate Of the State of Arizona acting for and on behalf Of Arizona State University Compound arrays for sample profiling
CN102597238B (zh) 2009-06-24 2016-06-29 库尔纳公司 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CN102762731B (zh) 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
KR101827015B1 (ko) 2009-08-11 2018-02-07 큐알엔에이, 인크. 아디포넥틴(ａｄｉｐｏｑ)에 대한 천연 안티센스 전사체의 억제에 의한 아디포넥틴(ａｄｉｐｏｑ) 관련된 질환의 치료
EP2982755B1 (en) 2009-08-21 2020-10-07 CuRNA, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
JP5964232B2 (ja) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド ‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
AU2010287069B2 (en) 2009-08-27 2016-07-07 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen Methanobrevibacter ruminantium
GB0915332D0 (en) 2009-09-02 2009-10-07 Univ Leuven Kath New methods for diagnosing autoimmune diseases
WO2011038210A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
US9366667B2 (en) 2009-10-02 2016-06-14 The Trustees Of Columbia University In The City Of New York Piscine reovirus diagnostic compositions
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
CN102695526A (zh) 2009-11-09 2012-09-26 吉恩波多治疗股份公司 用于神经元特异性的体内连续dopa合成的新型病毒载体构建体
CN103755809B (zh) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
KR101823702B1 (ko) 2009-12-16 2018-01-30 큐알엔에이, 인크. 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
CA2785177C (en) 2009-12-29 2019-09-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
CN102782134B (zh) 2009-12-29 2017-11-24 库尔纳公司 通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
JP6083735B2 (ja) 2009-12-31 2017-02-22 カッパーアールエヌエー，インコーポレイテッド インスリン受容体基質２（ｉｒｓ２）および転写因子３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるインスリン受容体基質２（ｉｒｓ２）関連疾患の治療
WO2011082409A2 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
EP2524039B1 (en) 2010-01-11 2017-11-29 CuRNA, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
RU2611192C2 (ru) 2010-01-25 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
GB201004850D0 (en) 2010-03-23 2010-05-05 Natural Environment Res Council Proteins
CA2795145C (en) 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
TWI644675B (zh) 2010-04-09 2018-12-21 可娜公司 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR101915115B1 (ko) 2010-05-03 2018-11-05 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CN102971423B (zh) 2010-05-26 2018-01-26 库尔纳公司 通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病
PT2585596T (pt) 2010-06-23 2021-03-23 Curna Inc Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CN103210086B (zh) 2010-10-06 2017-06-09 库尔纳公司 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
WO2012051306A2 (en) 2010-10-12 2012-04-19 Gencia Corporation Compositions and methods for modulating mitochondrial proteases
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
KR102010598B1 (ko) 2010-11-23 2019-08-13 큐알엔에이, 인크. Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
JP5980810B2 (ja) 2010-12-29 2016-09-07 インターベット インターナショナル ベー． フェー． イヌバベシア症ワクチン抗原
GB201104669D0 (en) 2011-03-18 2011-05-04 Medical Res Council Technology Compound
CA2831136A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
WO2012142526A1 (en) 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
DK201370709A (en) 2011-04-21 2013-11-20 Univ Aberdeen Protein for use as a medicament
US8975293B2 (en) 2011-05-26 2015-03-10 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
CA2838588C (en) 2011-06-09 2021-09-14 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
KR101941724B1 (ko) 2011-07-14 2019-01-23 얀센 백신스 앤드 프리벤션 비.브이. 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
AR087811A1 (es) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv Vacuna contra el staphylococcus aureus
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
CA2849267A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
EP2748307A4 (en) 2011-09-23 2015-08-19 Univ Louisville Res Found METHODS AND COMPOSITIONS FOR CELL EXPANSION AND GRAFT ENHANCEMENT
KR102102862B1 (ko) 2011-10-14 2020-04-22 제넨테크, 인크. 항-HtrA1 항체 및 사용 방법
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
PL396675A1 (pl) 2011-10-17 2013-04-29 Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Pan Gen Grainyhead-like 1 i czynnik transkrypcyjny Grainyhead-like 1 do zastosowania w regulowaniu cisnienia krwi u ssaków
CA2852631A1 (en) 2011-10-28 2013-05-02 Itek Ventures Pty Ltd A gene and mutations thereof associated with seizure and movement disorders
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
WO2013113865A1 (en) 2012-02-03 2013-08-08 The Pirbright Institute Eimeria vector vaccine for campylobacter jejuni
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
JP6253596B2 (ja) 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
KR20140136488A (ko) 2012-03-15 2014-11-28 큐알엔에이, 인크. 뇌 유래 신경영양 인자（ｂｄｎｆ）에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자（ｂｄｎｆ）관련 질환의 치료
CA2860994A1 (en) 2012-03-16 2013-09-19 Klaus P. Hoeflich Methods of treating melanoma with pak1 inhibitors
RU2014141617A (ru) 2012-03-16 2016-05-10 Дженентек, Инк. Сконструированные конформационно-стабилизированные белки
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
DK2838998T3 (da) 2012-04-18 2018-01-15 Cell Signaling Technology Inc Egfr og ros1 i kræft
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP2900692A1 (en) 2012-09-27 2015-08-05 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20160228528A1 (en) 2013-01-28 2016-08-11 Janssen Sciences Ireland Uc A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MY197809A (en) 2013-03-15 2023-07-18 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
SG10201808523RA (en) 2013-03-15 2018-11-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
JP6715766B2 (ja) 2013-06-21 2020-07-01 ザ ジョンズ ホプキンス ユニバーシティ ヒト膜蛋白質の機能および相互作用をプロファイリングするためのビリオンディスプレイアレイ
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015166036A1 (en) 2014-05-02 2015-11-05 Morphosys Ag Peptide libraries
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
WO2016001389A1 (en) 2014-07-02 2016-01-07 Inflectis Bioscience Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
SI3164391T1 (sl) 2014-07-02 2019-12-31 InFlectis BioScience, O-alkil-benzilidengvanidinski derivati in terapevtska uporaba za zdravljenje motenj, povezanih z nabiranjem napačno zvitih proteinov
JP6673896B2 (ja) 2014-07-15 2020-03-25 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物
EP3188746A4 (en) 2014-09-05 2018-05-02 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
US10704098B2 (en) 2014-10-29 2020-07-07 The Children's Hospital Of Philadelphia Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
WO2016090300A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
AU2016214304B2 (en) 2015-02-05 2021-11-11 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
CA2981068C (en) 2015-03-26 2021-12-14 Women & Infants Hospital Of Rhode Island Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CA3025145A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
EP3311165B1 (en) 2015-06-19 2020-12-09 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
WO2017035017A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
IL295097A (en) 2015-10-30 2022-09-01 Genentech Inc Anti-htra1 antibodies and methods of using them
EP3371211A4 (en) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CA3026844A1 (en) 2016-06-15 2017-12-21 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted tricyclic heterocyclic compounds and use thereof
EP3472201A4 (en) 2016-06-20 2020-05-13 Healthtell Inc. METHOD FOR DIFFERENTIAL DIAGNOSIS OF AUTOIMMUNE DISEASES
EP3472181A4 (en) 2016-06-20 2020-05-13 Healthtell Inc. METHOD FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
EP3538893A4 (en) 2016-11-11 2020-09-23 Healthtell Inc. PROCESSES FOR IDENTIFYING CANDIDATE BIOMARKERS
CA3082255A1 (en) 2016-11-23 2020-06-10 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
GB201622362D0 (en) 2016-12-29 2017-02-15 Medical Res Council Tech Compounds
GB201622365D0 (en) 2016-12-29 2017-02-15 Medical Res Council Tech Compounds
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
EP3596117A4 (en) 2017-03-17 2021-01-13 The Johns Hopkins University TARGETED EPIGENETIC THERAPY AGAINST THE DISTAL EXPRESSION REGULATORY ELEMENT OF TGFB2
JP7248588B2 (ja) 2017-04-21 2023-03-29 ジェネンテック， インコーポレイテッド 疾患の治療のためのｋｌｋ５アンタゴニストの使用
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
ES2947336T3 (es) 2017-09-01 2023-08-07 Univ Johns Hopkins Terapia epigenética dirigida para el aneurisma aórtico hereditario
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
CN113166269A (zh) 2018-11-13 2021-07-23 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
CA3127072A1 (en) 2019-01-16 2020-07-23 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
EP3917571A4 (en) 2019-01-31 2022-10-12 Agency For Science, Technology And Research CNX/ERP57 INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CANCER
CA3141531A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
EP4061414A1 (en) 2019-11-20 2022-09-28 Intervet International B.V. A novel vaccine against heamophilus parasuis
EP4061415A1 (en) 2019-11-20 2022-09-28 Intervet International B.V. A novel vaccine against heamophilus parasuis
BR112022009507A2 (pt) 2019-11-20 2022-08-16 Intervet Int Bv Uma nova vacina contra heamophilus parasuis
JP2023545566A (ja) 2020-10-20 2023-10-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１軸結合アンタゴニストとｌｒｒｋ２阻害剤との併用療法
JP2023547220A (ja) 2020-10-29 2023-11-09 蘇州亜宝薬物研発有限公司 置換ジアリールアミン化合物及びその医薬組成物、製造方法と用途
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
EP4351582A1 (en) 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
IL310662A (en) 2021-08-23 2024-04-01 Immunitas Therapeutics Inc Anti-CD161 antibodies and their uses
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115727A (en) * 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
US4438208A (en) * 1982-05-27 1984-03-20 The Regents Of The University Of California Region-specific determinants for vitamin K dependent bone protein
US4544629A (en) * 1982-11-19 1985-10-01 Minnesota Mining And Manufacturing Company Receptor-based histamine assay
US4504586A (en) * 1983-02-03 1985-03-12 Amgen Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences

Also Published As

Publication number Publication date
US5595915A (en) 1997-01-21
EP0138855B1 (en) 1991-11-27
CA1220420A (en) 1987-04-14
JPS60500684A (ja) 1985-05-09
EP0138855B2 (en) 1999-09-08
DK532284A (da) 1984-11-08
NZ207394A (en) 1987-03-06
EP0138855A4 (en) 1986-02-10
DK164529C (da) 1992-11-23
NO844296L (no) 1984-10-29
DK164529B (da) 1992-07-06
EP0138855A1 (en) 1985-05-02
NO166466B (no) 1991-04-15
WO1984003564A1 (en) 1984-09-13
ATE69890T1 (de) 1991-12-15
DE3485299D1 (de) 1992-01-09
JPH063445B2 (ja) 1994-01-12
NO166466C (no) 1991-07-24

Similar Documents

Publication Publication Date Title
DK532284D0 (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
NL300153I1 (nl) Voor Factor VIIIC coderende DNA-sequenties en verwante DNA-constructen.
EP0330506A3 (en) Vla proteins
KR850006548A (ko) 프리(pre)-S 유전자 코우드로 된 펩티드 B형 간염 면역원, 왁찐, 진단법 및 합성지질소낭 담체
DK0658168T3 (da) Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
ES2059330T3 (es) Un cdna codificador de antigeno carcinoembrionico.
EP0253325A3 (en) Oncogene-related peptides
ES8606411A1 (es) Procedimiento para la determinacion de fibrina
DK0547059T3 (da) Pankreas-elastase-1-specifikt antistof, fremgangsmåde til udvinding deraf og testkit indeholdende så danne antistoffer
DK0418590T3 (da) Antistoffer, fremstilling deraf og anvendelse deraf
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
NO910479D0 (no) Syntetiske polypeptider og antistoffer relatert til epstein-barr-virus-kjerneantigen.
KR960014341A (ko) 톡소플라즈마 곤디의 항원
DE68926813T2 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
Albiach et al. Multiple use of blotted polyvinylidene difluoride membranes immunostained with nitro blue tetrazolium
Lu STUDIES ON THE STRUCTURE AND FUNCTION OF GLUCOSEPHOSPHATE ISOMERASES: CHEMICAL MODIFICATIONS, CHEMICAL CLEAVAGES AND STRUCTURAL ANALYSES.
DE3485972T2 (de) Antigen aktive aminosaeuresequenzen.

Legal Events

Date Code Title Description
PUP Patent expired